Neuphoria Therapeutics Inc (NEUP) Q3 2024 Earnings Report

Previous: Q2 2024 Next: Q1 2026

Neuphoria Therapeutics

NEUP

$4.27 0.00%

Exchange: NASDAQ | Sector: Healthcare | Industry: Medical Pharmaceuticals

Q3 2024

Published: Mar 31, 2025

Earnings Highlights

Revenue of $15.00M up 0% year-over-year
EPS of $0.05 increased by 244.9% from previous year
Gross margin of 98.9%
Net income of 11.26M
"Transcript not available in provided materials." - N/A

NEUP

Company NEUP

Period Q3 2024

Currency USD

Report Type Quarterly Earnings

Generated Dec 8, 2025

Executive Summary

Neuphoria Therapeutics reported a landmark QQ3 2024 with revenue of $15.0 million, delivering a gross margin of 98.9% and an EBITDA of $11.35 million. Net income reached $11.26 million and earnings per share (diluted) were $0.048. The quarter marks a dramatic QoQ revenue uplift from the prior quarter, implying a potential one-time licensing or milestone-related revenue event or highly compressed costs relative to top-line growth. The company also exhibits substantial liquidity, ending the period with roughly $8.5 million in cash and cash equivalents and $15.5 million in cash and short-term investments, underpinning a strong balance sheet with minimal leverage.

Key Performance Indicators

Revenue

Stable

15.00M

QoQ: 2 163.42% | YoY: N/A

Gross Profit

Stable

14.84M

98.90% margin

QoQ: 2 138.52% | YoY: N/A

Operating Income

Increasing

11.98M

QoQ: 423.40% | YoY: 363.07%

Net Income

Increasing

11.26M

QoQ: 679.52% | YoY: 347.28%

EPS

Increasing

0.05

QoQ: 679.52% | YoY: 244.88%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: $15,000,000; QoQ growth: ~2,163% (from $0.663M in Q2 2024 to $15.0M in QQ3 2024). Gross profit: $14,835,000; Gross margin: 98.9%. EBITDA: $11,346,000; EBITDA margin: 75.64%. Operating income: $11,977,000; operating margin: 79.85%. Net income: $11,262,000; net margin: 75.08%. EPS (diluted): $0.0481; Weighted avg shares: 234,011,728. Cash flow: operating cash flow -$3,349,269; net change in cash -$1,732,565; free cash flow -$3,295,061. Ending cash: $8,503,792; cash and short-term investments: $15,541,172. Current ratio: 11.01; Quick ratio: 11.01; Debt ratio: 0.0056. Price/metrics snapshot: P/S ~89.86x; P/Book ~51.85x; Enterprise value multiple ~117.31x.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	15.00M	N/A	2 163.42%
Gross Profit	14.84M	N/A	2 138.52%
Operating Income	11.98M	363.07%	423.40%
Net Income	11.26M	347.28%	679.52%
EPS	0.05	244.88%	679.52%

Key Financial Ratios

Gross Profit Margin

Excellent

98.90%

Gross profit margin is exceptional, indicating strong pricing power and operational efficiency

Operating Profit Margin

Excellent

79.80%

Operating margin is exceptional, indicating strong pricing power and operational efficiency

Net Profit Margin

Excellent

75.10%

Net profit margin is exceptional, indicating strong pricing power and operational efficiency

Return on Assets

Strong

36.70%

Return on assets demonstrates excellent capital efficiency and value creation

Return on Equity

Strong

43.30%

Return on equity demonstrates excellent capital efficiency and value creation

Current Ratio

Strong

11.01

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.01

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Growth

29.92x

Elevated P/E suggests growth expectations or premium valuation

Price to Book

High Premium

51.85x

Very high premium suggests asset-light business model or lofty expectations

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q1 2026	0.00	-4.41	+0.0%	View
Q3 2024	15.00	0.05	+0.0%	View
Q2 2024	0.66	-0.01	+0.0%	View
Q1 2024	0.00	0.00	+0.0%	View
Q3 2023	0.00	-0.02	+0.0%	View

NEUP

Neuphoria Therapeutics

Q1 2026 Report

Neuphoria Therapeutics Inc (NEUP) QQ1 2026 Results: Cash Runway, R&D Burn and Pipeline Progress in a Pre-Revenue Clinical-Stage Biotech...

Read full report

NEUP

Neuphoria Therapeutics

Q2 2024 Report

Neuphoria Therapeutics Inc (NEUP) QQ2 2024 Results — Minimal Revenue, Escalating R&D Spend, and Financing-Driven Cash Position...

Read full report

NEUP

Neuphoria Therapeutics

Q1 2024 Report

Neuphoria Therapeutics Inc (NEUP) QQ1 2024 Results — Clinical-Stage Biotech Burn, Liquidity Cushion, and Early-Stage Outlook...

Read full report

NEUP

Neuphoria Therapeutics

Q3 2023 Report

Neuphoria Therapeutics Inc (NEUP) QQ3 2023 Results – Early-Stage Neuropsychiatric Pipeline Facing Ongoing R&D Burn and Modest Near-Term Revenue...

Read full report

Neuphoria Therapeutics (NEUP) Q3 2024 Earnings Report

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More NEUP Quarterly Reports

NEUP

NEUP

NEUP

NEUP

Related Financial Data

Sector Analysis: Healthcare

NEUP Full Profile

NEUP Financial Statements

Earnings Calendar